Emapalumab

Drug Profile

Emapalumab

Alternative Names: NI-0501

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovImmune SA
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophagocytic lymphohistiocytosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Haemophagocytic lymphohistiocytosis

Most Recent Events

  • 18 Oct 2017 NovImmune plans a phase III trial for Haemophagocytic lymphohistiocytosis (In Neonates, In infants, In children, In adolescents) (IV) in January 2018
  • 09 Oct 2017 Novimmune initiates enrolment in a phase II trial for Haemophagocytic lymphohistiocytosis (First-line therapy, In adolescents, In children, In infants) in Spain (EudraCT2016-004223-23)
  • 05 Sep 2017 The US FDA grants Rare paediatric disease designation to empalumab for Haemophagocytic lymphohistiocytosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top